Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity. The larger dataset is expected to better assess ORR, PFS and biomarkers, with updates anticipated through 2026–2027.
How this was made
The 30-second read
Why it matters
The key market signal is the decision to increase sample size based on continued safety/tolerability and preliminary clinical activity, which should strengthen future efficacy and biomarker analyses.
Market read
A straightforward clinical development catalyst: larger Phase 1b enrollment for paxalisib in TNBC after encouraging tolerability, setting up richer ORR/PFS and biomarker readouts.
What to watch
Abstract withdrawal for IP reasons may reduce near-term conference-driven attention, potentially muting follow-through despite the trial expansion.
Background
Kazia is developing paxalisib (PI3K/Akt/mTOR inhibitor) in multiple oncology indications, including brain-penetrant settings; this update targets advanced triple-negative breast cancer with immunotherapy and chemotherapy.
Ticker impact
Kazia plans to expand its Phase 1b paxalisib trial in advanced TNBC, increasing enrollment from 12 to 36 after encouraging safety/tolerability data.
Near-term bias upward on trial-expansion optimism; magnitude likely limited by Phase 1b size and open-label nature.
The company explicitly increases planned enrollment based on ongoing safety/tolerability and expects more meaningful efficacy/biomarker assessment, which is a direct catalyst for clinical-stage biotech trading.
Market effects
Supports read-across optimism for PI3K/mTOR pathway inhibitors in combination immunotherapy settings, though evidence remains early-stage.
Primarily impacts US-listed small-cap biotech sentiment; limited direct regional spillover beyond clinical oncology investors.
International relevance via TNBC and immune-combination strategy; however, the update is company-specific and early.
Counterpoint
Enrollment expansion does not guarantee efficacy; Phase 1b open-label results may still fail to translate into durable ORR/PFS improvements.
Key entities
- companyKazia Therapeutics
Clinical-stage oncology company expanding its paxalisib Phase 1b trial in advanced TNBC.
- drugpaxalisib
Investigational PI3K/Akt/mTOR pathway inhibitor being tested in combination regimens.
- drugpembrolizumab
Checkpoint inhibitor used in combination with paxalisib and chemotherapy in the expanded cohort.
